TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.97
−4.11%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$0.98
From 52W high−36.70%
Volume99667.00
Market cap$43.72M
P/E (TTM)—
P/S (TTM)0.5x
Div yield—
Key dataOct 16, 2026
Open
$0.98
From 52W high
−36.70%
Volume
99667.00
Market cap
$43.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
42.5
MomentumView details →
1D Return
−4.11%
YTD Return
−16.86%
SummaryUpdated Jun 1, 2026
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company founded in 2012 and headquartered in Malvern, Pennsylvania. The company went public in November 2019 and specializes in developing and commercializing soft-tissue reconstruction solutions for hernia repair and plastic surgery applications. TELA Bio focuses on providing alternatives to traditional synthetic mesh products by offering reinforced tissue matrices derived from natural ovine (sheep) tissue combined with synthetic materials to optimize patient outcomes while preserving anatomical integrity.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted 510(k) clearance to TELA Bio's Liora Monofilament Scaffold for soft tissue reinforcement.11d agoTELA Bio, Inc. obtained a limited consent from Perceptive Credit Holdings V, LP and the consenting lenders waiving the minimum revenue covenant under its credit agreement for the fiscal quarters ending on or about September 30, 2026 and December 31, 2026.17d agoTELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.46d ago